RGEN - Repligen EPS beats by $0.30 beats on revenue

Repligen (NASDAQ:RGEN): Q3 Non-GAAP EPS of $0.78 beats by $0.30; GAAP EPS of $0.58 beats by $0.10. Revenue of $178.22M (+89.5% Y/Y) beats by $14.25M. Shares +0.52% PM. Press Release Inorganic revenue from acquisitions made in 2020 and 2021 accounted for 6% of revenue. Adjusted gross margin increased to 58.3%. Adjusted operating margin was 32%, an increase of 340 bps. Raised FY 2021 Outlook: Total revenue is expected to be in the range of $655-$665 million, an increase from our previous guidance of $625-$645 million. We expect overall revenue growth of 79%-82% and 77%-80% at constant currency. Organic growth is expected to be in the range of 65%-68%, an increase from our previous guidance of 57%-62%. Gross margin is expected to be in the range of 59%-60% on both a GAAP and non-GAAP basis, consistent with our previous guidance. Fully diluted GAAP EPS is expected to be in the range of $2.19-$2.24,

For further details see:

Repligen EPS beats by $0.30, beats on revenue